Maravai LifeSciences (MRVI) Tops Q1 EPS by 4c

Maravai LifeSciences (NASDAQ: MRVI) reported Q1 EPS of $0.24, $0.04 better than the analyst estimate of $0.20. Revenue for the quarter came in at $148.2 million versus the consensus estimate of $138.49 million.

GUIDANCE:

Maravai LifeSciences sees FY2021 EPS of $1.04-$1.12, versus the consensus of $0.89. Maravai LifeSciences sees FY2021 revenue of $680-720 million, versus the consensus of $610.97 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• Bath & Body Works rises as Citi upgrades stock ahead of earnings